Disorders of fluids and electrolytes: Vasopressin antagonists

New England Journal of Medicine

Volumn 372, Issue 23, 2015, Pages 2207-2216

  Berl, Tomas ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; TOLVAPTAN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; SODIUM; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

BINDING AFFINITY; BINDING SITE; CONSTIPATION; DEMYELINATING DISEASE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; FLUID INTAKE; HUMAN; HYPERVOLEMIA; HYPONATREMIA; INHIBITION CONSTANT; LIVER INJURY; NAUSEA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; XEROSTOMIA; BLOOD; HISTORY; PHYSIOLOGY; PRACTICE GUIDELINE;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPONATREMIA; PRACTICE GUIDELINES AS TOPIC; SODIUM; VASOPRESSINS;

EID: 84930526374     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1403672     Document Type: Review

References (65)

1. Von de Velden V. Die Nierenwirkung von hypophyseuxtrakten beim menschen. Herl kiln Wochnschr 1913;1:2083-6. (In German.)
2. Oliver G, Schäfer EA. On the physiological action of extracts of pituitary body and certain other glandular organs. J Physiol 1895;18:277-9.
3. Howell WH. The physiological effects of extracts of the hypophysis cerebri and infundibular body. J Exp Med 1898;3:245-58.
4. Verney EB. The antidiuretic hormone and the factors which determine its release. Proc R Soc Lond B Biol Sci 1947;135:25-106.
5. Jewell PA, Verney EB. An experimental attempt to determine the site of neurohypophyseal osmorereceptors in the dog. Phil Trans Roy Soc 1957;240:197-324.
6. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-F332.
7. Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973;52:3212-9.
8. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529-42.
9. Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982;72:339-53.
10. Turner RA, Pierce JG, du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem 1951;191:21-8.
11. Schmale H, Richter D. Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 1984;308:705-9.
12. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994;269:3304-10.
13. Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992;357:333-5.
14. Agre P. The aquaporin water channels. Proc Am Thorac Soc 2006;3:5-13.
15. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549-52.
16. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989;114:617-32.
17. Stassen FL, Bryan W, Gross M, et al. Critical differences between species in the in vivo and in vitro renal responses to antidiuretic hormone antagonists. Prog Brain Res 1983;60:395-403.
18. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-91.
19. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent: a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-9.
20. Thibonnier M, Coles P, Conarty DM, Plesnicher CL, Shoham M. A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor. J Pharmacol Exp Ther 2000;294:195-203.
21. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001;41:175-202.
22. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 2006;316:564-71.
23. Pinto CS, Reif GA, Nivens E, White C, Wallace DP. Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells. Am J Physiol Renal Physiol 2012;303:F1412-F1424.
24. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
25. Tahara A, Saito M, Sugimoto T, et al. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998;357:63-9.
26. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-7.
27. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev 2009;14:75-82.
28. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-57.
29. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
30. Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis 2010;56:325-37.
31. Jaber BL, Almarzouqi L, Borgi L, Seabra VF, Balk EM, Madias NE. Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. Am J Med 2010;124(10):977.e1-977.e9.
32. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014;29:Suppl 2:i1-i39.
33. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-12.
34. Greenberg A, Verbalis J, Amin A, et al. Hyponatremia: current treatment practice and outcomes report of the hyponatremia registry: an observational multicenter international study. Kidney Int 2015 February 11.
35. rd ed. Philadelphia: Saunders, 2008:337-52.
36. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant 2010;25:1524-31.
37. Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7:742-7.
38. Dominguez M, Perez JA, Patel CB. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals. Methodist Debakey Cardiovasc J 2013;9:49-53.
39. Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013;19:390-7.
40. Food and Drug Administration. FDA safety communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death, 2013 (http://www.fda.gov/Drugs/DrugSafety/ucm350062.htm).
41. Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-5.
42. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31.
43. Malhotra I, Gopinath S, Janga KC, et al. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans. Case Rep Endocrinol 2014;2014:807054.
44. Lehrich RW, Ortiz-Melo DI, Patel MB, Greenberg A. Role of vaptans in the management of hyponatremia. Am J Kidney Dis 2013;62:364-76.
45. Di Benedetto G, See M. Direct Healthcare Professional Communication on the risk of increases in serum sodium with tolvaptan (Samsca) which are too rapid, March 26, 2012 (http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con146921.pdf).
46. Decaux G. V2-antagonists for the treatment of hyponatraemia. Nephrol Dial Transplant 2007;22:1853-5.
47. Serradeil-Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996;98:2729-38.
48. Gottschalk CW, Mylle M. Micropuncture study of the mammalian urinary concentrating mechanism: evidence for the countercurrent hypothesis. Am J Physiol 1959;196:927-36.
49. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-90.
50. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007;18:606-12.
51. Fenske WK, Christ-Crain M, Hörning A, et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. J Am Soc Nephrol 2014;25:2376-83.
52. Nagler EV, Vanmassenhove J, van der Veer SN, et al. Diagnosis and treatment of hyponatremia: a systematic review of clinical practice guidelines and consensus statements. BMC Med 2014;12:1.
53. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126:Suppl 1:S1-S42.
54. Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Opin 2014;30:1201-7.
55. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71.
56. Cyr PL, Slawsky KA, Olchanski N, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm 2004;68:328-3.
57. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-32.
58. Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000;319:240-4.
59. Steele A, Gowrishankar M, Abrahamson S, Mazer CD, Feldman RD, Halperin ML. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997;126:20-5.
60. Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM 1998;91:749-53.
61. Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treatment of hyponatremia. Kidney Int 2013;83:563-7.
62. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119(1):71.e1-71.e8.
63. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008;101:583-8.
64. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 2008;19:764-70.
65. Hoorn EJ, Zietse R. Hyponatremia and mortality: how innocent is the bystander? Clin J Am Soc Nephrol 2011;6:951-3.